HC Wainwright Maintains Buy Rating on Atrium Therapeutics
HC Wainwright maintained its Buy rating and $20 price target on Atrium Therapeutics. The target implies 140.4% upside from the Oct. 27 close of $8.32.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.